Polymorphisms of NFκB1 and IκBα and Their Synergistic Effect on Nasopharyngeal Carcinoma Susceptibility
Table 2
Stratification analysis of the number of risk genotypes in NFκB1/IκBα by selected variables in NPC patients and controls.
Patients ( = 1590)
Controls ( = 1979)
Adjusted OR (95% CI)a
0b
1b
2b
0b
1b
2b
0b
1b
2b
(%)
(%)
(%)
(%)
(%)
(%)
Age (years)
<50
86 (13.0)
425 (64.2)
151 (22.8)
145 (17.0)
578 (67.6)
132 (15.4)
1.00 (ref.)
1.27 (0.94–1.72)
1.88 (1.31–2.71)
3.47 ×
≥50
118 (12.7)
607 (65.4)
203 (21.9)
186 (16.5)
754 (67.1)
184 (16.4)
1.00 (ref.)
1.25 (0.97–1.63)
1.83 (1.34–2.51)
2.56 ×
Sex
Male
135 (11.9)
743 (65.7)
253 (22.3)
232 (16.5)
946 (67.4)
226 (16.1)
1.00 (ref.)
1.35 (1.07–1.71)
1.98 (1.49–2.63)
1.57 ×
Female
69 (15.0)
289 (63.0)
101 (22.0)
99 (17.2)
386 (67.1)
90 (15.7)
1.00 (ref.)
1.06 (0.77–1.56)
1.60 (1.07–2.20)
1.32 ×
Family history of cancer
YES
12 (7.3)
106 (64.2)
47 (28.5)
27 (15.8)
120 (70.2)
24 (14.0)
1.00 (ref.)
1.74 (0.82–3.71)
3.92 (1.63–9.39)
9.60 ×
NO
192 (13.5)
926 (65.0)
307 (21.5)
304 (16.8)
1212 (67.0)
292 (16.2)
1.00 (ref.)
1.22 (1.00–1.50)
1.68 (1.31–2.15)
2.41 ×
Smoking status
Ever
98 (11.5)
579 (67.7)
178 (20.8)
158 (16.9)
630 (67.2)
149 (15.9)
1.00 (ref.)
1.50 (1.13–1.99)
1.95 (1.39–2.76)
1.33 ×
Never
106 (14.4)
453 (61.6)
176 (24.0)
173 (16.6)
702 (67.4)
167 (16.0)
1.00 (ref.)
1.05 (0.80–1.38)
1.70 (1.22–2.37)
8.41 ×
Drinking status
Ever
103 (13.2)
497 (63.8)
179 (23.0)
98 (16.2)
415 (68.5)
93 (15.3)
1.00 (ref.)
1.13 (0.83–1.53)
1.80 (1.23–2.62)
1.36 ×
Never
101 (12.4)
535 (66.0)
175 (21.6)
233 (17.0)
917 (66.8)
223 (16.2)
1.00 (ref.)
1.35 (1.04–1.74)
1.81 (1.33–2.47)
1.31 ×
EBV infection
Positive
161 (13.0)
791 (63.8)
287 (23.2)
57 (17.0)
222 (66.1)
57 (16.9)
1.00 (ref.)
1.27 (0.91–1.79)
1.74 (1.14–2.66)
8.91 ×
Negative
43 (12.2)
241 (68.7)
67 (19.1)
274 (16.7)
1110 (67.6)
259 (15.8)
1.00 (ref.)
1.39 (0.97–1.98)
1.69 (1.10–2.58)
0.017
Stages
I
8 (10.3)
52 (66.7)
18 (23.1)
331 (16.7)
1332 (67.3)
316 (16.0)
1.00 (ref.)
1.55 (0.80–3.43)
2.35 (1.02–5.46)
0.039
II
51 (12.1)
279 (66.3)
91 (21.6)
1.00 (ref.)
1.35 (0.98–1.88)
1.81 (1.27–2.73)
8.58 ×
III
90 (13.0)
451 (65.1)
152 (21.9)
1.00 (ref.)
1.25 (0.96–1.62)
1.79 (1.32–2.44)
1.35 ×
IV
58 (14.6)
239 (60.1)
101 (25.3)
1.00 (ref.)
1.03 (0.73–1.38)
1.84 (1.28–2.64)
2.97 ×
Compared with zero risk genotype, ORs were adjusted in a logistic regression model that included age, sex, smoking status, drinking status, and family history of cancer. bGenotype combinations of the two polymorphisms in the NFκB1 and IκBα: ins variant genotypes rs28362491 (ins/del + ins/ins) and rs696AA genotype are defined as risk genotypes: i.e., the carriers of rs28362491 del/del and rs696 GG/AG have zero risk genotype; the carriers of ins/del (ins/ins) and rs696 GG/AG, or del/del and rs696AA have one risk genotype; and the ins/del (ins/ins) and rs696AA carriers have two risk genotypes. cTrend test for NPC risk, with number of risk genotypes in each stratum.
